XML 44 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 7 - Stockholders' Equity (Deficit) (Details Textual)
3 Months Ended 9 Months Ended
Jul. 27, 2016
$ / shares
shares
Jun. 27, 2016
$ / shares
shares
Apr. 15, 2016
$ / shares
shares
Feb. 12, 2016
USD ($)
$ / shares
shares
Sep. 30, 2016
$ / shares
shares
Mar. 31, 2016
USD ($)
Sep. 30, 2016
USD ($)
$ / shares
shares
Jun. 26, 2016
$ / shares
shares
Dec. 31, 2015
$ / shares
shares
Reverse Stock Split [Member] | Series B Preferred Stock [Member]                  
Stockholders' Equity Note, Stock Split, Conversion Ratio 15,463.7183                
Reverse Stock Split [Member]                  
Stockholders' Equity Note, Stock Split, Conversion Ratio   15,463.7183              
Stock Conversion from Series B Preferred Stock to Common Stock [Member]                  
Convertible Preferred Stock, Shares Issued upon Conversion 1 1              
The 2006 Plan [Member] | Employee Stock Option [Member] | Minimum [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period         1 year        
The 2006 Plan [Member] | Employee Stock Option [Member] | Maximum [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period         5 years        
The 2006 Plan [Member] | Employee Stock Option [Member] | Chief Financial Officer [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period       3 years          
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period       10 years          
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting, Number of Monthly Installments       35          
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting, Monthly Installment, Shares       0.18          
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting, Final Monthly Installment, Shares       2,778          
Allocated Share-based Compensation Expense | $           $ 5,192 $ 10,383    
The 2006 Plan [Member] | Employee Stock Option [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized         2,000,000   2,000,000    
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period         10 years        
The 2006 Plan [Member] | Chief Financial Officer [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross       100,000          
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares       $ 1.25          
The 2006 Plan [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number         2,592,229   2,592,229   1,707,744
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross             1,301,084    
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares             $ 1.25    
Employee Stock Option [Member] | Minimum [Member] | Employees and Consultants [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period     10 years            
Employee Stock Option [Member] | Maximum [Member] | Employees and Consultants [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period     1 year            
Employee Stock Option [Member] | Each Member of Board of Directors [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period     2 years            
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period     10 years            
Employee Stock Option [Member] | Employees and Consultants [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period     4 years            
Employee Stock Option [Member] | Former Executives [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period         3 years        
Employee Stock Option [Member]                  
Allocated Share-based Compensation Expense | $             $ 450,566    
Each Member of Board of Directors [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross     40,000            
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares     $ 1.25            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Additional     5,000            
Director [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross     175,000            
Employees and Consultants [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross     1,008,299            
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares     $ 1.25            
Former Executives [Member]                  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross         17,785        
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares         $ 1.25        
Protagenic Therapeutics Inc [Member] | Private Placement [Member]                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       3,403,367          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares       $ 1.05          
Protagenic Therapeutics Inc [Member] | Predecessor Warrants [Member]                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       295,945          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares       $ 1.25          
Protagenic Therapeutics Inc [Member] | Placement Agent Warrants [Member]                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       127,346          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares       $ 1.25          
Protagenic Therapeutics Inc [Member]                  
Business Combination, Stock Warrant Conversion Ratio       1          
Debt Instrument, Face Amount | $       $ 665,000          
Debt Instrument, Increase, Accrued Interest | $       $ 35,000          
Class of Warrant or Right, Expiration Period       5 years          
Private Placement [Member] | Placement Agent Warrants [Member] | Series B Preferred Stock [Member]                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights     127,346            
Private Placement [Member] | Placement Agent Warrants [Member]                  
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares     $ 1.25            
Private Placement [Member] | Series B Preferred Stock [Member]                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       423,291          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares       $ 1.25          
Class of Warrant or Right, Expiration Period       5 years          
Predecessor Warrants [Member] | Series B Preferred Stock [Member]                  
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       295,945          
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares       $ 1.25          
Common Stock, Shares Authorized 100,000,000 100,000,000     100,000,000   100,000,000 100,000,000,000 100,000,000
Common Stock, Par or Stated Value Per Share | $ / shares $ 0.0001 $ 0.0001   $ 0.0001 $ 0.0001   $ 0.0001 $ 0.000001 $ 0.0001
Preferred Stock, Shares Authorized 20,000,000 20,000,000     20,000,000   20,000,000 5,000,000,000 20,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross             1,974,445    
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares             $ 1.25    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares             133,229